Male Hypogonadism: How to Stop Testosterone Treatment Safely

What Happens to the Body When TRT Stops

Exogenous testosterone shuts down the HPG axis through negative feedback on the hypothalamus and pituitary. GnRH pulse frequency drops. LH and FSH secretion fall, sometimes to undetectable levels within two weeks of starting therapy. When TRT stops, that suppression does not lift immediately.

Recovery depends on duration of therapy, the ester or formulation used, patient age, and baseline testicular reserve. Short courses (under six months) tend to recover faster. Men who used TRT for more than two years may wait nine months or longer before endogenous testosterone returns to pre-treatment range. The 2018 Endocrine Society Clinical Practice Guideline notes that "recovery of the hypothalamic-pituitary-gonadal axis after cessation of testosterone therapy is variable and may be prolonged" [1].

The HPG Axis Suppression Timeline

Testosterone cypionate or enanthate, the most commonly prescribed injectable formulations in the United States, have half-lives of approximately 8 days and 4.5 days respectively [2]. After a final injection, serum testosterone falls below 300 ng/dL within roughly 14 to 21 days. LH and FSH remain suppressed for longer because the pituitary needs time to regain sensitivity to GnRH after prolonged negative feedback.

Transdermal gels clear faster, typically within 48 to 72 hours of the last application, but HPG axis recovery timelines are similar because the suppression is driven by cumulative duration of use, not residual drug levels.

Why Abrupt Cessation Causes Rebound Symptoms

Men who stop TRT without a transition plan frequently experience severe fatigue, loss of libido, depressed mood, hot flashes, and cognitive fog within two to four weeks. These symptoms reflect hypogonadal testosterone levels before endogenous production recovers. A 2015 analysis published in the Journal of Clinical Endocrinology and Metabolism found that mean serum testosterone in men who stopped TRT after long-term use dropped to 165 ng/dL at week four before beginning a slow upward trend [3]. That trough is well below the symptomatic threshold and explains why unmanaged discontinuation carries a high rate of treatment restart without clinical justification.

Deciding Whether to Stop: Clinical Indications

Not every man on TRT should or needs to stop. The decision to discontinue should be driven by clinical criteria, not convenience. Common indications include newly diagnosed prostate cancer, erythrocytosis with hematocrit persistently above 54%, desire for fertility, or an original diagnosis that no longer meets criteria on repeat evaluation.

Secondary Hypogonadism vs. Primary Hypogonadism

Men with primary hypogonadism (Klinefelter syndrome, bilateral orchiectomy, or severe testicular failure) have little to no residual Leydig cell capacity. For them, stopping TRT is rarely appropriate outside of specific clinical scenarios such as prostate cancer diagnosis. Recovery of endogenous testosterone after stopping is unlikely, and the conversation is about transition to a different androgen formulation rather than true discontinuation [4].

Men with secondary hypogonadism (pituitary or hypothalamic dysfunction, obesity-related suppression, or functional hypogonadism) are the primary candidates for a managed taper and HPG axis restart because their testes retain some functional capacity.

Confirming the Original Diagnosis Before Stopping

The Endocrine Society guideline recommends repeating the diagnostic workup before initiating any discontinuation protocol. Two morning fasting total testosterone measurements below 300 ng/dL with consistent symptoms are required to confirm active hypogonadism [1]. If the original diagnosis was based on a single low-normal value or was drawn in the afternoon, the patient may not meet criteria for continued therapy, making discontinuation appropriate from the outset.

The Structured Discontinuation Protocol

A supervised taper reduces the severity and duration of the hypogonadal trough after stopping TRT. No large randomized controlled trials have evaluated TRT discontinuation protocols specifically, but the principles are drawn from HPG axis physiology and the fertility restoration literature [5].

Step 1: Final Testosterone Dose and Clearance Window

For injectable testosterone cypionate or enanthate, the last injection should be given at normal scheduled timing. There is no evidence that a dose reduction of the last injection speeds HPG recovery. After the final injection, allow 21 days for testosterone to clear to near-physiological or sub-physiological levels before initiating recovery agents.

For transdermal gels, discontinue abruptly on the planned date. Serum levels fall within 48 to 72 hours. Recovery agents can begin within 72 hours of the final application.

Step 2: Adjunct Agents to Restart the HPG Axis

Two agents are used off-label to accelerate HPG axis recovery after TRT cessation.

Clomiphene citrate blocks estrogen receptors at the hypothalamus and pituitary, removes negative feedback, and increases GnRH pulse frequency. A standard protocol uses 25 to 50 mg orally every day or every other day for 4 to 8 weeks. A 2019 study in the Journal of Urology (N=48) found that clomiphene citrate 25 mg daily restored testosterone to above 300 ng/dL in 74% of men with secondary hypogonadism within 12 weeks, without the spermatogenesis suppression associated with TRT [6].

Human chorionic gonadotropin (hCG) acts as an LH analog and directly stimulates Leydig cells, bypassing the pituitary. Protocols typically use 1,500 to 3,000 IU subcutaneously three times weekly for 6 to 12 weeks. HCG is particularly useful when there is concern about testicular atrophy after prolonged TRT. A 2013 paper in Fertility and Sterility demonstrated that hCG co-administration during TRT maintained intratesticular testosterone at levels adequate to preserve spermatogenesis, supporting its role in recovery after cessation as well [7].

Some clinicians use a sequential protocol: hCG for the first four weeks, then transition to clomiphene for weeks five through twelve.

Step 3: Monitoring Labs Post-Discontinuation

Labs should be drawn fasting, between 7 and 10 a.m., to capture peak endogenous testosterone.

| Timepoint | Labs to Order | |---|---| | Baseline (day of last dose) | Total T, free T, LH, FSH, SHBG, hematocrit, PSA | | Week 4 | Total T, LH, FSH | | Week 12 | Total T, free T, LH, FSH, SHBG | | Week 24 (if slow recovery) | Total T, LH, FSH, semen analysis if fertility desired |

If total testosterone remains below 200 ng/dL at week 12 with normal or elevated LH and FSH, primary testicular failure is likely and TRT restart should be discussed [1].

Managing Withdrawal Symptoms During Recovery

The hypogonadal trough is the hardest part of discontinuation. Testosterone may fall below 150 ng/dL before the HPG axis restores enough endogenous production to reach 300 ng/dL. Symptoms during this window include fatigue, low mood, decreased libido, night sweats, and reduced muscle strength.

Non-Hormonal Symptom Support

Lifestyle measures reduce symptom severity. Resistance training three to four times per week supports testosterone biosynthesis and maintains muscle mass during the recovery window [8]. Sleep optimization is particularly important because 70 to 80% of daily testosterone secretion occurs during slow-wave sleep, and sleep fragmentation further suppresses LH pulsatility.

Zinc supplementation at 25 to 45 mg elemental zinc per day may modestly support testosterone production in zinc-deficient men, though the evidence in eugonadal men is weak. Data in hypogonadal men are limited to small trials.

When to Consider Restarting TRT

Restart is appropriate when total testosterone remains below 300 ng/dL at week 24, symptoms are significantly impairing quality of life, and the original diagnosis has been reconfirmed on two morning samples. Restart for convenience, impatience with the recovery timeline, or a single borderline lab result should not drive the decision. The Endocrine Society emphasizes that treatment decisions should be based on the combination of biochemical and clinical criteria, not either one alone [1].

Fertility Recovery After TRT Cessation

TRT suppresses spermatogenesis by eliminating intratesticular testosterone, which requires LH stimulation at concentrations far above serum levels. Azoospermia develops in roughly 40% of men within six months of starting TRT and in a greater proportion with longer use [9]. Recovery after cessation is common but not guaranteed.

Spermatogenesis Recovery Timeline

A 2020 systematic review in Andrology (15 studies, N=1,549) found that 67% of men recovered to a sperm concentration above 20 million/mL within 12 months of TRT cessation, and 90% recovered within 24 months [9]. Men under age 40 with shorter TRT duration had faster recovery.

HCG-based restart protocols are strongly preferred over watchful waiting in men actively pursuing fertility. HCG alone or combined with FSH (follitropin alfa 75 IU three times weekly) represents the standard off-label approach when spermatogenesis recovery is the primary goal.

Semen Analysis Timing

A baseline semen analysis should be ordered no earlier than four weeks after TRT cessation, as spermatogenesis takes 72 to 74 days for a full cycle. Meaningful improvement in sperm count will not appear until at least 10 to 12 weeks post-discontinuation. Repeat analysis at six-month intervals is recommended until fertility goals are met or alternative diagnoses are pursued.

Special Populations and Considerations

Men With Obesity or Metabolic Syndrome

Functional hypogonadism driven by obesity is the most reversible subtype. In a 2014 trial published in the European Journal of Endocrinology (N=100), men with obesity and low testosterone who lost more than 10% of body weight through caloric restriction and exercise saw mean total testosterone rise from 243 ng/dL to 347 ng/dL without any pharmacologic intervention at 52 weeks [10]. For these men, stopping TRT while implementing aggressive lifestyle modification is often sufficient, and adjunct pharmacologic restart may be unnecessary.

Men on TRT for Longer Than Five Years

Prolonged suppression carries a higher risk of persistent hypogonadism after cessation. Testicular volume decreases measurably after 12 to 18 months of TRT, and Leydig cell atrophy may be only partially reversible. Clinicians should counsel these patients that full HPG axis recovery may take 12 to 18 months and that restart of TRT remains on the table if recovery is incomplete by month eighteen.

Men With Type 2 Diabetes or Metabolic Syndrome

The TRAVERSE trial (N=5,246, median follow-up 33 months), published in the New England Journal of Medicine in 2023, found that testosterone therapy in men with hypogonadism and pre-existing cardiovascular risk did not increase major adverse cardiovascular events compared to placebo (hazard ratio 0.96, 95% CI 0.78 to 1.17) [11]. Cessation in this group should still be managed carefully because the metabolic benefits of TRT (improved insulin sensitivity, body composition) may reverse within 6 to 12 months of stopping, potentially worsening glycemic control.

The HealthRX Discontinuation Decision Framework

The following framework is used by the HealthRX medical team to guide TRT discontinuation decisions. It is not a replacement for individualized clinical evaluation.

Step A. Confirm indication for stopping. Document the clinical reason: oncologic (prostate cancer diagnosis), hematologic (hematocrit above 54%), fertility goal, or diagnostic reassessment.

Step B. Classify hypogonadism subtype. Primary hypogonadism (elevated LH/FSH at baseline before TRT) has low recovery potential. Secondary or functional hypogonadism has meaningful recovery potential and is the primary candidate for this protocol.

Step C. Select recovery agent based on goal. If fertility is the goal, start hCG 1,500 to 3,000 IU three times weekly within 72 hours of last gel application or 21 days after last injection. If fertility is not the goal but symptom mitigation is, clomiphene citrate 25 to 50 mg daily is the preferred agent.

Step D. Order labs at weeks 4 and 12. Interpret total testosterone in the context of LH and FSH. A rising LH with rising testosterone signals successful HPG axis recovery. A high LH with persistently low testosterone signals primary testicular failure.

Step E. Decision at week 24. If total testosterone is above 300 ng/dL with resolution of symptoms, discontinue recovery agents and observe on six-month lab checks. If total testosterone remains below 300 ng/dL with persistent symptoms and two confirmatory morning samples, restart TRT with updated informed consent.

Erythrocytosis and Hematologic Safety After Stopping

TRT raises hematocrit through erythropoiesis stimulation. The FDA label for testosterone products warns that hematocrit should be checked at three to six months after starting TRT and periodically thereafter, with dose reduction or cessation recommended if hematocrit exceeds 54% [2]. After stopping TRT, hematocrit typically returns toward baseline within three to four months as the erythropoietic effect resolves.

Men who stopped TRT specifically for erythrocytosis do not always need phlebotomy if hematocrit is below 56% and they are asymptomatic. Lab rechecks at six and twelve weeks post-discontinuation are sufficient in most cases. If hematocrit exceeds 56% or the patient is symptomatic (headache, visual changes, hyperviscosity symptoms), phlebotomy to a target hematocrit of 48 to 50% is appropriate before full TRT cessation resolves the underlying driver [12].

PSA and Prostate Monitoring Around Discontinuation

Serum PSA drops by a median of 0.3 to 0.5 ng/mL within four weeks of stopping TRT. This drop can temporarily obscure clinically significant PSA elevations. Any man who was diagnosed with prostate cancer while on TRT, or who has a rising PSA trend on TRT, requires urologic consultation before and after discontinuation. The Endocrine Society guideline recommends PSA monitoring at three and twelve months after TRT initiation and annually thereafter, with discontinuation triggered by PSA rise above 1.4 ng/mL per year or absolute PSA above 4.0 ng/mL [1].

After stopping, PSA should be rechecked at four weeks and three months to establish a new baseline off-therapy. Biopsy decisions should be deferred until the PSA has stabilized off TRT, typically by week twelve.